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There is limited information on the outcome when organs other than heart or kidneys are involved by
immunoglobulin light-chain amyloidosis (AL). We report the outcome of 53 patients with AL with gastro-
intestinal (GI), peripheral nerve (PN), liver, lung, or soft-tissue involvement, who underwent high-dose
chemotherapy and autologous hematopoietic stem cell transplantation (auto-HCT) at our institution be-
tween 1997 and 2013. The median age at auto-HCT was 56 years (range, 35 to 74). One, 2, 3, or 4 organs were
involved in 43%, 22%, 28%, and 4% of patients, respectively. Concurrent cardiac, renal, or both were involved in
24 (45%) patients. Forty-six patients received induction therapy before auto-HCT. The 100-day and 1-year
treatment-related mortality (TRM) were 3.8% (n ¼ 2) and 7.5% (n ¼ 4), respectively. Forty-one (80%) pa-
tients achieved a hematologic response. Organ response at 1 year after auto-HCT was seen in 23 (57%) of the
40 evaluable patients. With a median follow-up of 24 months, the median progression-free survival and
overall survival (OS) were 36 and 73 months, respectively. Auto-HCT was associated with a low TRM, durable
organ responses, and a median OS of > 6 years in selected patients with AL and GI, PN, liver, lung, or soft-
tissue involvement.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
Immunoglobulin light-chain systemic amyloidosis (AL) is
a monoclonal plasma cell disorder characterized by the
deposition of misfolded immunoglobulin free light chains as
amyloid ﬁbrils [1]. These free light chains are secreted by the
clonal plasma cells and accumulate in multiple organs,
causing organ dysfunction. The aim of therapy in AL is to
reduce the production of misfolded light chains and preserve
the function of involved organs. The treatment of AL is
patterned after the treatment of multiple myeloma, anotherdgments on page 1417.
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ty for Blood and Marrow Transplantation.clonal plasma cell disorder. The treatment include the use of
conventional cytotoxic chemotherapy agents, such as
melphalan and cyclophosphamide, in standard doses [2,3];
immunomodulatory agents (IMiD), including thalidomide
[4] and lenalidomide [5]; the proteasome inhibitor (PI) bor-
tezomib [6] in combination with corticosteroids; and high-
dose melphalan, followed by autologous hematopoietic
stem cell transplantation (auto-HCT). Auto-HCT has been
associated with longer survival in selected patients when
compared with conventional chemotherapy agents [7-10]
and is considered an effective treatment strategy that has
been associated with hematologic response and an
improvement in organ function [8], quality of life, and sur-
vival [11]. However, in the only phase 3 randomized trial,
published by Jaccard et al., the outcome with high-dose
melphalan plus auto-HCT was not superior to standard-
dose melphalan plus dexamethasone [12]. This trial was
Table 1
Clinical Characteristic
Clinical characteristic Group n (%)
Age, yr <56 25 (27)
56 28 (53)
Sex Male 32 (60)
Female 21 (40)
Light-chain subtype Kappa 19 (36)
Lambda 32 (60)
Unknown 2 (4)
dFLC (mg/dL) before transplantation <18 21 (40)
18 21 (40)
Unknown 11 (20)
Bone marrow <10% 21 (40)
10% 32 (60)
Bone marrow amyloid Absence 36 (68)
Presence 17 (32)
b2 microglobulin (mg/mL) <3.5 36 (68)
3.5 16 (30)
Unknown 1 (2)
Serum creatinine (mg/dL) <2 47 (89)
2 6 (11)
Urine protein 24 h (g/d) 1 35 (66)
>1 17 (32)
Unknown 1 (2)
Albumin serum <3.5 15 (28)
3.5 38 (72)
Alkaline phosphatase 126 40 (75.5)
>126 13 (24.5)
Induction type Novel* 33 (62)
Conventional 13 (25)
No induction 7 (13)
Melphalan dose (mg/m2) <200 7 (13)
200 46 (87)
Number of involved organ (including
heart and kidney)
1 23 (43)
2 12 (23)
3 15 (28)
4 3 (6)
* Novel therapy deﬁned as IMid or PI-based therapy alone or in
combinations.
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(TRM) rate (24%) in the high-dose melphalan group, a rate
that was more than twice the rate in centers performing
auto-HCT for AL. That study was also notable for the inclu-
sion of patients with more than 3 involved organs, a sub-
optimal dose of high-dose melphalan in 10 of 37 patients,
and the inclusion of transplantation centers that perform 1
or fewer auto-HCT for AL in a year. Previous reports on the
outcome of high-dose therapy and auto-HCT in AL have
primarily focused on patients with cardiac or renal involve-
ment [13,14]. Limited data are available on the role of auto-
HCT when organs other than heart and kidneys are
involved by AL. In this study, we evaluated the role of high-
dose melphalan followed by auto-HCT in patients with
gastrointestinal tract (GI), peripheral nerves (PN), liver, lung,
or soft-tissue involvement by AL.
MATERIALS AND METHODS
Patients and Diagnosis
Diagnosis of AL was established by Congo red staining for amyloid ﬁbrils
with concomitant demonstration of plasma cell clonality by serum free light
chain (FLC) studies, serum immunoﬁxation electrophoresis, and bone
marrow biopsy and immunohistochemistry (CD138, kappa or lambda FLC
predominance), according to the criteria established at the 10th Interna-
tional Symposium on Amyloid and Amyloidosis [15,16]. In selected cases,
FLC origin of amyloid ﬁbrils was conﬁrmed by mass spectrometry or elec-
tron miscroscopy.
Involvement of individual organs (GI, PN, liver, lung, or soft tissue) by AL
was also established according to the criteria established at the 10th Inter-
national Symposium on Amyloid and Amyloidosis [15]. Patients with GI
involvement had endoscopic evaluation and biopsies. Patients with liver
involvement were evaluated by liver function tests; imaging studies
included computed tomography (CT) scans and ultrasound, and liver biopsy
when feasible. Patients with lung and soft-tissue involvement were evalu-
ated by imaging studies, including CT scan and biopsy of the involved organ,
when feasible. Patients with PN involvement were evaluated by electro-
myography (EMG), nerve conduction studies (NCS), and sural nerve biopsy
(2 patients) to conﬁrm the diagnosis. All patients underwent auto-HCT be-
tween 1997 and 2013 at the University of Texas MDAnderson Cancer Center.
Auto-HCT
The choice of preparative regimen was based on the patient’s perfor-
mance status and the treating physician’s preference. Patients received
high-dose melphalan at 200mg/m2 or 140 mg/m2 at the treating physician’s
discretion.
Hematologic and Organ Response Assessment
All patients underwent clinical, laboratory, and radiological evaluation
at baseline and at 100 days and 1 year post auto-HCT. Hematologic response
(HR) was deﬁned according to the International Myeloma Working Group
criteria [17]. Organ involvement and responses were deﬁned by the criteria
established at the 10th International Symposium on Amyloid and
Amyloidosis [15].
Statistical Analysis
The primary endpoint of this study was to assess the hematologic and
organ response after auto-HCT. TRM was deﬁned as death due to any cause
other than relapse of AL within 100 days or 1 year after auto-HCT. Overall
survival (OS) was deﬁned as time from auto-HCT to death or last follow-up.
Progression-free survival (PFS) was deﬁned as time from auto-HCT to disease
progression, death, or the last follow-up. Survival was estimated by using
the Kaplan-Meier method. Fisher’s exact test and chi-square test were used
for analyzing the differences between categorical variables. The associations
of multiple factors on OS were evaluated using the Cox proportional hazards
model. All P values were 2 tailed, and we accepted P  .05 as signiﬁcant. All
statistical analyses were performed using STATA (Stata Statistical Software:
Release 12. StataCorp LP, College Station, TX).
RESULTS
Patients
We identiﬁed 53 patients with AL who met the inclusion
criteria for these analyses. Patient characteristics aresummarized in Table 1. The median follow-up among sur-
viving patients was 25 months (range, 3 to 144).
Hematologic Involvement at Diagnosis
Thirty-two (60%) patients had lambda FLC subtype and 19
(36%) patients had kappa FLC subtype of AL. Serum FLC were
available in 42 (79%) patients before auto-HCT. The median
difference in involved and uninvolved FLC (dFLC) was 59
(range, 0 to 1237) before transplantation. As shown in
Table 1, 21 (39%) patients had a dFLC of < 18, whereas 21
(39%) patients had a dFLC of  18. Median plasma cell
percent in the bone marrow at diagnosis was 13% (range, 1 to
100).
Organ Involvement at Diagnosis
Organ involvement was deﬁned according to the Inter-
national Society of Amyloidosis criteria [15]. Clinical features
of organ involvement are summarized in Table 2. Patients
with GI involvement presented with abdominal mass,
bleeding, diarrhea, motility disturbance, nausea, or weight
loss. Upper or lower GI endoscopy was performed to conﬁrm
the diagnosis of AL. A limited number of patients also un-
derwent barium studies to evaluate the GI tract. Patients
with neurologic involvement had symmetrical peripheral
neuropathy or autonomic neuropathy. In selected patients,
EMG or NCS were also performed. Sural nerve biopsies were
also performed in 2 of 17 (12%) patients with peripheral
neuropathy. Patients with liver involvement presented with
Table 2
Clinical Presentation of the Involved Organs
Evaluation of the
Involved Organs
Clinical Laboratory Imaging Other
Kidney Generalized edema, ascites, dypnea Proteinuria
Biopsy
NA AL deposition on renal biopsy
Heart Dyspnea, pedal edema, fatigue Elevated NT-Pro BNP;
Troponin T or I
Echo Endomyocardial biopsy
Peripheral nerve Pain, tingling, numbness, paresthesis Nerve biopsy NA EMG, NCS
GI Diarrhea, nausea, weight loss, constipation Barium studies Upper or lower GI endoscopy
Soft tissue Tongue enlargement, lymph node
enlargement, muscle pain or weakness,
carpal tunnel syndrome
NA CT scan of the involved area Biopsy of the involved organ
Liver Hepatomegaly Abnormal liver
function tests
CT scan, ultrasound Liver biopsy
Lung Shortness of breath, hemoptysis NA CXR, CT scan PFT, lung biopsy
NA indicates not available; NT-Pro BNP, N-terminal of prohormone brain natriuretic peptide; Echo, echocardiogram; CXR, chest x-ray; PFT, pulmonary function
tests.
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times the upper limit of normal). Ultrasound or CT scans
were performed to conﬁrm hepatomegaly. Liver biopsy was
done if amyloid deposition was not conﬁrmed elsewhere.
Patients with lung involvement presented with either dys-
pnea or hemoptysis. They had diffuse interstitial inﬁltrates,
lung nodules, or mass lesions on imaging studies. Lung bi-
opsy was performed to conﬁrm the diagnosis. Patients with
soft-tissue involvement presented with either tongue
enlargement, paraspinal muscle mass, muscle weakness or
pain, diffuse skin nodules, or lymph node enlargement. Or-
gan involvement was further conﬁrmed by imaging studies,
including CT scans, and biopsy of the involved organ, if a
diagnosis of AL had not been established elsewhere.
Patients with cardiac involvement most commonly pre-
sented with symptoms of congestive heart failure, and the
diagnosis was established by an echocardiogram, cardiac
biomarkers, or endomyocardial biopsy in selected patients.
Patients with renal involvement most commonly presented
with generalized edema, with proteinuria >2 g/24 hours and
renal biopsy was performed in selected patients to conﬁrm
AL deposition.
Twenty-nine (55%) patients did not have heart or kidney
involvement at diagnosis. Twenty-three (43%) patients had a
single organ, which was not the heart or lung, involved. That
includes peripheral nerves (n ¼ 10), soft tissues including
lymphadenopathy, macroglossia, or skeletal muscles (n ¼ 5),
GI tract (n ¼ 4), liver (n ¼ 3), and lungs (n ¼ 1). Twelve (22%)
patients had 2, 15 patients (28%) had 3, and 3 patients (5%)
had 4 organs involved. There were 24 (45%) patients with
concurrent renal or cardiac involvement. Nine (17%) patients
had concurrent heart and kidney, 9 (17%) patients had heart,
and 6 (11%) had kidney involvement in addition to the organs
described in this paper.
Induction Therapy
Overall, 33 (62%) patients received pretransplantation
induction therapy with either an IMiD or a PI, 13 (25%)Table 3
Organ Response to Auto-HCT
Organ Involved n (%) No. Evaluable (%) Or
GI 24 (45) 21 (87.5) 11
Peripheral nerve 17 (32) 16 (94) 8
Liver 8 (15) 6 (75) 5
Lungs 5 (9) 5 (100) 4
Soft tissue 17 (32) 15 (88) 7received conventional chemotherapy and 7 (13%) received no
induction prior to auto-HCT. In 33 patients who received
induction with either a PI or IMiD, 14 (26%) patients received
a bortezomib-based regimen, 9 (17%) patients received bor-
tezomib in combination with lenalidomide or thalidomide,
10 (18%) received an IMiD-based regimen (lenalidomide [n ¼
8], thalidomide [n ¼ 2]) without bortezomib. The median
duration of induction therapy before auto-HCT was 3.6
months.
TRM
The 100-day TRM was 3.8% (n ¼ 2). One patient died of
sepsis and multiple organ failure and the other was due to
thrombotic thrombocytopenic purpura. The 1-year TRM was
7.5% (n¼ 4). Twomore patients died between 100-day and 1-
year evaluations. One patient died of sepsis, and the cause of
death was unclear for the second patient.
HR
The HR was evaluated 100 days after auto-HCT. Two pa-
tients died before the 100-day evaluation. According to In-
ternational Myeloma Working Group criteria [17], of the 51
evaluable patients, 41 (80%) achieved an HR ( partial
response). Ten (20%) patients achieved a complete response
(CR), 11 (21%) a very good partial response, and 20 (39%)
achieved a partial response. Serum FLC assays were available
in 42 (79%) patients both before and after auto-HCT. The
median dFLC was 59 (range, 0 to 1237) before and 30.5
(range, .2 to 553) after the auto-HCT.
Organ Response
Organ response was evaluated at 100 days and 1 year
after auto-HCT. The response was assessed by clinical, labo-
ratory imaging, and other diagnostic tests to meet the
response criteria established by the 10th International
Symposium on Amyloid and Amyloidosis [15]. Organ
response in at least 1 organ was seen in 30 (59%) of the 51
evaluable patients at 100 days and in 23 (57%) of the 40gan Response (%) Stable Disease (%) Progressed (%)
(52) 9 (43) 1 (5)
(50) 8 (50) 0
(83) 0 1 (17)
(80) 1 (20) 0
(47) 7 (47) 1 (6)
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Figure 1. Median overall survival from auto-HCT.
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had an organ response evaluation at 1 year because 4 pa-
tients died before the 1-year landmark and 9 patients were
unable to return to our institution for detailed and reliable
response evaluation. Organ response at the 100-day evalu-
ationwas seen in 26 of 41 (63%) patients with an HR and in 4
of 10 (40%) patients (4 of 10) without a HR (P¼ .20). Details of
organ response are summarized below. There was resolution
of GI symptoms (nausea, vomiting, malabsorption, diarrhea)
in 11 (52%) patients with GI involvement. There was an
improvement in paresthesias and orthostatic hypotension in
8 (50%) patients with PN involvement, with improvement in
EMG and NCS in selected patients. In patients with liver
involvement, there was a 4 cm decrease in liver span in 1
patient and at least 50% decrease in alkaline phosphatase
value in 4 patients. In patients with lung involvement, 4
(80%) had an organ response, with resolution or signiﬁcant
improvement of pulmonary inﬁltrates and nodules on CT
scans, and improvement in symptoms and pulmonary
function tests In patients with soft-tissue involvement, 7
(47%) had an organ response with improvement in or reso-
lution of tongue swelling, dysphagia, lymphadenopathy, skin
nodules, and muscle pain or swelling (Table 3).
Survival
The median OS after auto-HCT was 73 months (Figure 1).
The median PFS was 36 months (Figure 2). In landmark
analysis, starting at 100 days after auto-HCT, the median OS
for 41 patients with a HR at day 100was 90months versus 34
months in 10 patients without a HR (P ¼ .40). The median OS0
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Figure 2. Median progression-free survival from auto-HCT.was 94 months for 30 patients with an organ response at day
100 versus 64 months in 21 patients without an organ
response (P ¼ .05). In landmark analysis starting at 1 year
after auto-HCT, the median OS was 81months for 23 patients
with an organ response at 1 year versus 55 months for 17
patients without an organ response (P ¼ .04).
Factors Predicting Survival before Auto-HCT
On univariate analysis for 2-year OS, we evaluated the
following variables: number of organs involved, percentage
of plasma cell in bone marrow, FLC subtype (kappa, lambda),
24-hour urine total protein value, b2 microglobulin, and
serum albumin value at diagnosis and dFLC value before
auto-HCT. None of the factors analyzed had a statistically
signiﬁcant impact on the outcome (Table 4).
DISCUSSION
We report the clinical characteristic and outcomes of 53
patients with AL with involvement of at least 1 of these 5
organs: GI, PN, liver, lungs, and soft tissues. Our results
demonstrate that selected patients receiving auto-HCT can
achieve durable hematologic and organ responses, with a
long OS and relatively low TRM.
HR was seen in 80% patients [17], which is comparable to
previous studies in similar patients [18-20]. Gertz et al. re-
ported an overall hematologic and organ response of 64% in a
multicenter trial that enrolled 30 patients [21]. In another
study reported from the Mayo Clinic, 76% patients achieved
HR, including 38.7% achieving CR [19]. Although overall HR in
our study was comparable to other groups, the CR rate was
somewhat lower (24%) than reported by others. This rela-
tively lower CR rate may be due to several factors, such as
response evaluation soon after auto-HCT underestimating
the actual response, higher disease burden, and the use of
lower melphalan dose in 13% of patients before auto-HCT.
Organ response in at least 1 organ was seen in 59% of pa-
tients, which also compares favorably with other reports
[19,22]. Vesole et al. reported a functional improvement in at
least 1 organ in 36% (28 of 77) patients at 100 days after auto-
HCT [22]. Gertz et al. reported outcomes of 434 patients with
ALwho underwent transplantation since 1996, and the organ
response rate was 46.8% [19]. Some studies have shown a
direct correlation between HR, organ response, and OS
[11,23]. Although our result showed a direct correlation be-
tween organ response and OS, there was no signiﬁcant as-
sociation between HR and organ response.Table 4
Univariate Analysis for Two-Year Overall Survival
Variable Group Hazard
Ratio
95% CI P Value
No. of organ involvement 1-2 Ref. .30
3-4 1.9 .5-7.3
Bone marrow PC% <10 1.4 .4-5.4 .60
10 Ref.
FLC subtype Kappa .3 .03-2.2 .20
Lambda Ref.
dFLC (mg/dL) before
transplantation
<18 .4 .1-2 .25
18 Ref.
Urine protein 24 h (g/d) <1 .4 .1-1.4 .10
1 Ref.
b2 microglobulin (mg/mL) <3.5 .3 .1-1.2 .09
3.5 Ref.
Albumin serum (g/dL) <3.5 2.3 .6-8.6 .20
3.5 Ref.
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patientswith cardiac or renal involvementwho received auto-
HCT [24,25]. Organ response in patients with renal involve-
ment was 29% in 1 year after auto-HCT. One-year TRM in
patients with cardiac involvement was less than 4%. In this
study, we focused on the characteristics and outcomes of or-
gans affected by AL that are relatively difﬁcult for response
assessment. Using the standard published criteria, encour-
aging responses were seen in the affected organs that were
durable in most patients, with a low TRM. In general, AL is
associated with high TRM after an auto-HCT [26,27]. In a
meta-analysis conducted by Comenzo et al. [28], 100-day TRM
were 21% and 39% in single and multicenter clinical trials,
respectively. However, a risk-adapted approach to high-dose
melphalan signiﬁcantly reduced the risk of TRM after auto-
HCT [27]. The low TRM (3.4%) in our study may be attrib-
uted to the inclusion of patients with noncardiac AL,
improvement in supportive care, and melphalan dose reduc-
tion in patients with older age or signiﬁcant comorbidities.
Our study had the usual limitations of a retrospective
chart review, including a heterogeneous population, poten-
tial selection bias, and perhaps inclusion of relatively good-
risk patients who were able to undergo high-dose
melphalan and less than one third had cardiac involvement.
In conclusion, our results support the use of high-dose
melphalan followed by auto-HCT in selected patients with
AL. We report the durable HR, organ responses, a median OS
of > 6 years with low TRM.
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